Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 101

1.

Midazolam Limited Sampling Strategy With a Population Pharmacokinetic Approach to Simultaneously Estimate Cytochrome P450 (CYP) 3A Constitutive, Inhibition, and Induction/Activation Conditions in Healthy Adults.

Yang J, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Stoch SA, Bertino JS Jr, Nafziger AN, Ma JD.

J Clin Pharmacol. 2019 Nov;59(11):1495-1504. doi: 10.1002/jcph.1440. Epub 2019 May 3.

PMID:
31051051
2.

4β-Hydroxycholesterol as an Endogenous Biomarker for CYP3A Activity: Literature Review and Critical Evaluation.

Penzak SR, Rojas-Fernandez C.

J Clin Pharmacol. 2019 May;59(5):611-624. doi: 10.1002/jcph.1391. Epub 2019 Feb 12. Review.

PMID:
30748026
3.

The Importance of Authentic Leadership to all Generations Represented within Academic Pharmacy.

Pinelli NR, Sease JM, Nola K, Kyle JA, Heldenbrand SD, Penzak SR, Ginsburg DB.

Am J Pharm Educ. 2018 Aug;82(6):6694. doi: 10.5688/ajpe6694.

4.

Correction to: Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.

Jann MW, Penzak SR.

CNS Drugs. 2018 Jun;32(6):603. doi: 10.1007/s40263-018-0531-7.

PMID:
29858836
5.

Potential Influence of Centrally Acting Herbal Drugs on Transporters at the Blood-Cerebrospinal Fluid Barrier and Blood-Brain Barrier.

Kibathi LW, Bae S, Penzak SR, Kumar P.

Eur J Drug Metab Pharmacokinet. 2018 Dec;43(6):619-635. doi: 10.1007/s13318-018-0486-6. Review.

PMID:
29858835
6.

Stability of isoniazid injection in i.v. solutions.

Lee JH, Moriyama B, Henning SA, Danner RL, Walsh TJ, Penzak SR, Grimes GJ, Potti GK.

Am J Health Syst Pharm. 2018 May 15;75(10):622-626. doi: 10.2146/ajhp170268.

PMID:
29748300
7.

Midazolam Single Time Point Concentrations to Estimate Exposure and Cytochrome P450 (CYP) 3A Constitutive Activity Utilizing Limited Sampling Strategy With a Population Pharmacokinetic Approach.

Yang J, Patel M, Nikanjam M, Capparelli EV, Tsunoda SM, Greenberg HE, Penzak SR, Aubrey Stoch S, Bertino JS Jr, Nafziger AN, Ma JD.

J Clin Pharmacol. 2018 Sep;58(9):1205-1213. doi: 10.1002/jcph.1125. Epub 2018 Apr 17.

PMID:
29663428
8.

Long-Acting Injectable Second-Generation Antipsychotics: An Update and Comparison Between Agents.

Jann MW, Penzak SR.

CNS Drugs. 2018 Mar;32(3):241-257. doi: 10.1007/s40263-018-0508-6. Review. Erratum in: CNS Drugs. 2018 Jun;32(6):603.

PMID:
29569082
9.

Differential Influence of the Antiretroviral Pharmacokinetic Enhancers Ritonavir and Cobicistat on Intestinal P-Glycoprotein Transport and the Pharmacokinetic/Pharmacodynamic Disposition of Dabigatran.

Kumar P, Gordon LA, Brooks KM, George JM, Kellogg A, McManus M, Alfaro RM, Nghiem K, Lozier J, Hadigan C, Penzak SR.

Antimicrob Agents Chemother. 2017 Oct 24;61(11). pii: e01201-17. doi: 10.1128/AAC.01201-17. Print 2017 Nov.

10.

Response to "Impact of CYP3A4 Genotype on Voriconazole Exposure: New Insights Into the Contribution of CYP3A4*22 to Metabolism of Voriconazole".

Walsh TJ, Moriyama B, Penzak SR, Klein TE, Caudle KE.

Clin Pharmacol Ther. 2018 Feb;103(2):187. doi: 10.1002/cpt.811. Epub 2017 Nov 16. No abstract available.

PMID:
28786218
11.

Response to "Pharmacogenetics of Voriconazole: CYP2C19 but Also CYP3A4 Need to Be Genotyped" - The Role of CYP3A4 and CYP3A5 Polymorphisms in Clinical Pharmacokinetics of Voriconazole.

Walsh TJ, Moriyama B, Penzak SR, Klein TE, Caudle KE.

Clin Pharmacol Ther. 2017 Aug;102(2):190. doi: 10.1002/cpt.681. Epub 2017 Apr 29. No abstract available.

PMID:
28455946
12.

Therapeutic drug monitoring of posaconazole oral suspension in paediatric patients younger than 13 years of age: a retrospective analysis and literature review.

Jancel T, Shaw PA, Hallahan CW, Kim T, Freeman AF, Holland SM, Penzak SR.

J Clin Pharm Ther. 2017 Feb;42(1):75-79. doi: 10.1111/jcpt.12483. Epub 2016 Dec 16.

13.

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy.

Moriyama B, Obeng AO, Barbarino J, Penzak SR, Henning SA, Scott SA, Agúndez J, Wingard JR, McLeod HL, Klein TE, Cross SJ, Caudle KE, Walsh TJ.

Clin Pharmacol Ther. 2017 Jul;102(1):45-51. doi: 10.1002/cpt.583. Epub 2017 Apr 18. Erratum in: Clin Pharmacol Ther. 2018 Feb;103(2):349.

14.

Antiretroviral Boosting Agent Cobicistat Increases the Pharmacokinetic Exposure and Anticoagulant Effect of Dabigatran in HIV-Negative Healthy Volunteers.

Gordon LA, Kumar P, Brooks KM, Kellogg A, McManus M, Alfaro RM, Nghiem K, George JM, Lozier J, Penzak SR, Hadigan C.

Circulation. 2016 Dec 6;134(23):1909-1911. No abstract available.

15.

Pharmacokinetic Drug Interactions with Panax ginseng.

Ramanathan MR, Penzak SR.

Eur J Drug Metab Pharmacokinet. 2017 Aug;42(4):545-557. doi: 10.1007/s13318-016-0387-5. Review.

PMID:
27864798
16.

Novel in situ self-assembly nanoparticles for formulating a poorly water-soluble drug in oral solid granules, improving stability, palatability, and bioavailability.

Guo S, Pham K, Li D, Penzak SR, Dong X.

Int J Nanomedicine. 2016 Apr 7;11:1451-60. doi: 10.2147/IJN.S100621. eCollection 2016.

17.

Part 2 - Coronary angiography with gadofosveset trisodium: a prospective intra-subject comparison for dose optimization for 100 % efficiency imaging.

Ahlman MA, Raman FS, Pang J, Zemrak F, Sandfort V, Penzak SR, Fan Z, Liu S, Li D, Bluemke DA.

BMC Cardiovasc Disord. 2016 Mar 22;16:58. doi: 10.1186/s12872-015-0152-8.

18.

Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole.

Moriyama B, Kadri S, Henning SA, Danner RL, Walsh TJ, Penzak SR.

Curr Fungal Infect Rep. 2015 Jun;9(2):74-87. Epub 2015 Apr 16.

19.

Lack of an Effect of Ritonavir Alone and Lopinavir-Ritonavir on the Pharmacokinetics of Fenofibric Acid in Healthy Volunteers.

Gordon LA, Malati CY, Hadigan C, McLaughlin M, Alfaro RM, Calderón MM, Kovacs JA, Penzak SR.

Pharmacotherapy. 2016 Jan;36(1):49-56. doi: 10.1002/phar.1682.

20.

Efavirenz but Not Atazanavir/Ritonavir Significantly Reduces Atovaquone Concentrations in HIV-Infected Subjects.

Calderón MM, Penzak SR, Pau AK, Kumar P, McManus M, Alfaro RM, Kovacs JA.

Clin Infect Dis. 2016 Apr 15;62(8):1036-1042. doi: 10.1093/cid/ciw028. Epub 2016 Jan 20.

21.

Part 1 - Coronary angiography with gadofosveset trisodium: a prospective feasibility study evaluating injection techniques for steady-state imaging.

Ahlman MA, Raman FS, Penzak SR, Pang J, Fan Z, Liu S, Gai N, Li D, Bluemke DA.

BMC Cardiovasc Disord. 2015 Dec 22;15:177. doi: 10.1186/s12872-015-0176-0.

22.

Neither the HIV protease inhibitor lopinavir-ritonavir nor the antimicrobial trimethoprim-sulfamethoxazole prevent malaria relapse in plasmodium cynomolgi-infected non-human primates.

Hobbs CV, Dixit S, Penzak SR, Sahu T, Orr-Gonzalez S, Lambert L, Zeleski K, Chen J, Neal J, Borkowsky W, Wu Y, Duffy PE.

PLoS One. 2014 Dec 26;9(12):e115506. doi: 10.1371/journal.pone.0115506. eCollection 2014.

23.

Emerging drugs and vaccines for candidemia.

Moriyama B, Gordon LA, McCarthy M, Henning SA, Walsh TJ, Penzak SR.

Mycoses. 2014 Dec;57(12):718-33. doi: 10.1111/myc.12265. Epub 2014 Oct 8. Review.

24.

Influence of Panax ginseng on the steady state pharmacokinetic profile of lopinavir-ritonavir in healthy volunteers.

Calderón MM, Chairez CL, Gordon LA, Alfaro RM, Kovacs JA, Penzak SR.

Pharmacotherapy. 2014 Nov;34(11):1151-8. doi: 10.1002/phar.1473. Epub 2014 Aug 20.

25.

Enhanced neonatal Fc receptor function improves protection against primate SHIV infection.

Ko SY, Pegu A, Rudicell RS, Yang ZY, Joyce MG, Chen X, Wang K, Bao S, Kraemer TD, Rath T, Zeng M, Schmidt SD, Todd JP, Penzak SR, Saunders KO, Nason MC, Haase AT, Rao SS, Blumberg RS, Mascola JR, Nabel GJ.

Nature. 2014 Oct 30;514(7524):642-5. doi: 10.1038/nature13612. Epub 2014 Aug 13.

26.

HIV treatments reduce malaria liver stage burden in a non-human primate model of malaria infection at clinically relevant concentrations in vivo.

Hobbs CV, Neal J, Conteh S, Donnelly L, Chen J, Marsh K, Lambert L, Orr-Gonzalez S, Hinderer J, Healy S, Borkowsky W, Penzak SR, Chakravarty S, Hoffman SL, Duffy PE.

PLoS One. 2014 Jul 2;9(7):e100138. doi: 10.1371/journal.pone.0100138. eCollection 2014.

27.

Integrating pharmacogenetic information and clinical decision support into the electronic health record.

Goldspiel BR, Flegel WA, DiPatrizio G, Sissung T, Adams SD, Penzak SR, Biesecker LG, Fleisher TA, Patel JJ, Herion D, Figg WD, Lertora JJ, McKeeby JW.

J Am Med Inform Assoc. 2014 May-Jun;21(3):522-8. doi: 10.1136/amiajnl-2013-001873. Epub 2013 Dec 3.

28.

Evaluation of partial area under the concentration time curve to estimate midazolam apparent oral clearance for cytochrome P450 3A phenotyping.

Tai W, Gong SL, Tsunoda SM, Greenberg HE, Gorski JC, Penzak SR, Stoch SA, Ma JD.

Drug Metabol Drug Interact. 2013;28(4):217-23. doi: 10.1515/dmdi-2013-0040.

PMID:
24114901
29.

The effect of antiretrovirals on Plasmodium falciparum liver stages.

Hobbs CV, De La Vega P, Penzak SR, Van Vliet J, Krzych U, Sinnis P, Borkowsky W, Duffy PE.

AIDS. 2013 Jun 19;27(10):1674-7. doi: 10.1097/QAD.0b013e3283621dd4.

30.

Influence of low-dose ritonavir with and without darunavir on the pharmacokinetics and pharmacodynamics of inhaled beclomethasone.

Boyd SD, Hadigan C, McManus M, Chairez C, Nieman LK, Pau AK, Alfaro RM, Kovacs JA, Calderon MM, Penzak SR.

J Acquir Immune Defic Syndr. 2013 Jul 1;63(3):355-61. doi: 10.1097/QAI.0b013e31829260d6.

31.

Pharmacokinetics of intravenous voriconazole in obese patients: implications of CYP2C19 homozygous poor metabolizer genotype.

Moriyama B, Jarosinski PF, Figg WD, Henning SA, Danner RL, Penzak SR, Wayne AS, Walsh TJ.

Pharmacotherapy. 2013 Mar;33(3):e19-22. doi: 10.1002/phar.1192. Epub 2013 Feb 11.

32.

HIV nonnucleoside reverse transcriptase inhibitors and trimethoprim-sulfamethoxazole inhibit plasmodium liver stages.

Hobbs CV, Voza T, De La Vega P, Vanvliet J, Conteh S, Penzak SR, Fay MP, Anders N, Ilmet T, Li Y, Borkowsky W, Krzych U, Duffy PE, Sinnis P.

J Infect Dis. 2012 Dec 1;206(11):1706-14. doi: 10.1093/infdis/jis602.

33.

The postantifungal and paradoxical effects of echinocandins against Candida spp.

Moriyama B, Henning SA, Penzak SR, Walsh TJ.

Future Microbiol. 2012 May;7(5):565-9. doi: 10.2217/fmb.12.31.

PMID:
22568712
34.
35.

Lack of a pharmacokinetic drug-drug interaction with venlafaxine extended-release/indinavir and desvenlafaxine extended-release/indinavir.

Jann MW, Spratlin V, Momary K, Zhang H, Turner D, Penzak SR, Wright A, VanDenBerg C.

Eur J Clin Pharmacol. 2012 May;68(5):715-21. doi: 10.1007/s00228-011-1180-7. Epub 2011 Dec 16.

PMID:
22173281
36.

Adverse interactions between antifungal azoles and vincristine: review and analysis of cases.

Moriyama B, Henning SA, Leung J, Falade-Nwulia O, Jarosinski P, Penzak SR, Walsh TJ.

Mycoses. 2012 Jul;55(4):290-7. doi: 10.1111/j.1439-0507.2011.02158.x. Epub 2011 Nov 29. Review.

37.

The CXCR4 antagonist plerixafor corrects panleukopenia in patients with WHIM syndrome.

McDermott DH, Liu Q, Ulrick J, Kwatemaa N, Anaya-O'Brien S, Penzak SR, Filho JO, Priel DA, Kelly C, Garofalo M, Littel P, Marquesen MM, Hilligoss D, Decastro R, Fleisher TA, Kuhns DB, Malech HL, Murphy PM.

Blood. 2011 Nov 3;118(18):4957-62. doi: 10.1182/blood-2011-07-368084. Epub 2011 Sep 2.

38.

Influence of Panax ginseng on cytochrome P450 (CYP)3A and P-glycoprotein (P-gp) activity in healthy participants.

Malati CY, Robertson SM, Hunt JD, Chairez C, Alfaro RM, Kovacs JA, Penzak SR.

J Clin Pharmacol. 2012 Jun;52(6):932-9. doi: 10.1177/0091270011407194. Epub 2011 Jun 6.

39.

Prolonged half-life of voriconazole in a CYP2C19 homozygous poor metabolizer receiving vincristine chemotherapy: avoiding a serious adverse drug interaction.

Moriyama B, Falade-Nwulia O, Leung J, Penzak SR, JJingo C, Huang X, Henning SA, Wilson WH, Walsh TJ.

Mycoses. 2011 Nov;54(6):e877-9. doi: 10.1111/j.1439-0507.2011.02016.x. Epub 2011 May 25. No abstract available.

40.

Markers of endothelial dysfunction, coagulation and tissue fibrosis independently predict venous thromboembolism in HIV.

Musselwhite LW, Sheikh V, Norton TD, Rupert A, Porter BO, Penzak SR, Skinner J, Mican JM, Hadigan C, Sereti I.

AIDS. 2011 Mar 27;25(6):787-95. doi: 10.1097/QAD.0b013e3283453fcb.

41.

Pharmacokinetics of anidulafungin in pleural fluid during the treatment of a patient with Candida empyema.

Moriyama B, Ditullio M, Wilson E, Henning SA, Penzak SR, Danner RL, Pennick G, Rinaldi MG, Zelazny AM, Gea-Banacloche J, Barrett AJ, Walsh TJ.

Antimicrob Agents Chemother. 2011 May;55(5):2478-80. doi: 10.1128/AAC.01560-10. Epub 2011 Mar 14.

42.
43.

Echinacea purpurea significantly induces cytochrome P450 3A activity but does not alter lopinavir-ritonavir exposure in healthy subjects.

Penzak SR, Robertson SM, Hunt JD, Chairez C, Malati CY, Alfaro RM, Stevenson JM, Kovacs JA.

Pharmacotherapy. 2010 Aug;30(8):797-805. doi: 10.1592/phco.30.8.797.

44.

The pharmacodynamic equivalence of levothyroxine and liothyronine: a randomized, double blind, cross-over study in thyroidectomized patients.

Celi FS, Zemskova M, Linderman JD, Babar NI, Skarulis MC, Csako G, Wesley R, Costello R, Penzak SR, Pucino F.

Clin Endocrinol (Oxf). 2010 May;72(5):709-15. doi: 10.1111/j.1365-2265.2009.03700.x.

45.

Gemfibrozil concentrations are significantly decreased in the presence of lopinavir-ritonavir.

Busse KH, Hadigan C, Chairez C, Alfaro RM, Formentini E, Kovacs JA, Penzak SR.

J Acquir Immune Defic Syndr. 2009 Oct 1;52(2):235-9. doi: 10.1097/QAI.0b013e3181b0610e.

46.

Antiviral therapy in patients with hematologic malignancies, transplantation, and aplastic anemia.

Jancel T, Penzak SR.

Semin Hematol. 2009 Jul;46(3):230-47. doi: 10.1053/j.seminhematol.2009.03.004. Review.

PMID:
19549576
47.

Pharmacology and antifungal properties of anidulafungin, a new echinocandin.

Estes KE, Penzak SR, Calis KA, Walsh TJ.

Pharmacotherapy. 2009 Jan;29(1):17-30. doi: 10.1592/phco.29.1.17. Review.

PMID:
19113794
48.

Efavirenz induces CYP2B6-mediated hydroxylation of bupropion in healthy subjects.

Robertson SM, Maldarelli F, Natarajan V, Formentini E, Alfaro RM, Penzak SR.

J Acquir Immune Defic Syndr. 2008 Dec 15;49(5):513-9. doi: 10.1097/QAI.0b013e318183a425.

PMID:
18989234
49.

Influence of antiretroviral drugs on the pharmacokinetics of prednisolone in HIV-infected individuals.

Busse KH, Formentini E, Alfaro RM, Kovacs JA, Penzak SR.

J Acquir Immune Defic Syndr. 2008 Aug 15;48(5):561-6. doi: 10.1097/QAI.0b013e31817bebeb.

50.

Pharmacological enhancement of protease inhibitors with ritonavir: an update.

Busse KH, Penzak SR.

Expert Rev Clin Pharmacol. 2008 Jul;1(4):533-45. doi: 10.1586/17512433.1.4.533.

PMID:
24410555

Supplemental Content

Loading ...
Support Center